Chemotherapy Before Surgery Spares Most Patients Radiation for HPV-Linked Throat Cancer

A multicentre Phase II trial conducted in Japan has found that a three-drug chemotherapy regimen given before surgery allowed the overwhelming majority of patients with human papillomavirus (HPV)-associated oropharyngeal cancer to avoid postoperative radiotherapy and chemoradiotherapy altogether. The study, published in the British Journal of Cancer, tested neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, known as NAC-TPF, in patients with resectable HPV-positive oropharyngeal squamous cell carcinoma. The strategy produced pathologically confirmed complete responses in roughly two-thirds of participants and, crucially, enabled 91 percent of patients to finish treatment without any radiation at all, a result with major implications for quality of life in a cancer population that is typically young and expected to live for decades after cure.

Oropharyngeal squamous cell carcinoma, which arises in the tonsils and base of the tongue, has become increasingly common in developed countries, driven largely by HPV infection. Tumours linked to the virus respond unusually well to treatment, and patients with HPV-positive disease enjoy substantially better survival than those whose cancers are tobacco-related. That favourable biology has fuelled a worldwide effort to de-escalate therapy: if standard treatment cures more than 90 percent of patients, clinicians argue, the intensity of that treatment can perhaps be reduced without compromising outcomes. Radiation, even in modern intensity-modulated form, carries a heavy burden of long-term toxicity, including dry mouth, difficulty swallowing, neck stiffness, hypothyroidism, and, in some patients, the need for long-term feeding tubes.

Previous de-escalation attempts have taken two broad routes. One approach reduces the dose of radiation delivered after biopsy-definitive diagnosis, as tested in trials such as E1308 and OPTIMA, which used induction chemotherapy to select patients for reduced-dose chemoradiation. Another strategy replaces radiation with transoral surgery, exemplified by the E3311 trial of transoral robotic surgery with risk-based adjuvant therapy and the ORATOR randomised comparison of surgery versus radiotherapy. The Japanese trial takes a distinctive third path: it uses chemotherapy first to shrink the tumour, then performs less invasive transoral surgery, and withholds all postoperative radiation when pathology shows the disease has been eradicated.

In the trial, 32 eligible patients with HPV-associated resectable oropharyngeal cancer received three cycles of NAC-TPF before undergoing surgery. Thirty patients successfully underwent transoral surgery after the chemotherapy, and an R0 resection, meaning complete removal of the tumour with clear microscopic margins, was confirmed in 31 patients. The primary endpoint was the centrally reviewed pathological complete response rate, in which pathologists examine the surgical specimen and find no residual viable cancer. The pCR rate reached 65.6 percent, and a virological complete response, in which no high-risk HPV RNA could be detected in tumour specimens from either the primary site or the lymph nodes, was achieved in 64.5 percent of patients.

Although the trial formally missed its prespecified primary endpoint, the investigators concluded that the response rate was clinically meaningful and, more importantly, that the treatment sequence allowed 91 percent of patients to avoid postoperative radiotherapy or postoperative chemoradiotherapy entirely. For those patients, the entire course of cancer care consisted of chemotherapy followed by surgery, sparing them the swallowing dysfunction, xerostomia, and fibrosis that radiation to the throat typically causes. The trial was registered as jRCT1041220029 and was supported by the Japan Agency for Medical Research and Development, with participation from more than a dozen Japanese institutions including Shizuoka Cancer Center, National Cancer Center Hospital, and several university hospitals.

The study went beyond pathology to track molecular and patient-reported outcomes. Researchers measured levels of high-risk HPV RNA in tumour specimens and circulating tumour HPV DNA in blood plasma, an emerging biomarker that reflects fragments of DNA shed by tumour cells into the bloodstream. After neoadjuvant chemotherapy, 23 patients showed undetectable levels of circulating tumour HPV DNA, suggesting that the molecular footprint of the cancer had been eliminated in most participants. Liquid biopsy monitoring of this kind is increasingly viewed as a promising tool for identifying which patients can safely forgo intensive adjuvant therapy and for detecting recurrence earlier than imaging alone.

Quality of life was assessed prospectively using validated instruments, including the 30-item European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. All measured quality-of-life scores returned to baseline values or improved within one year of treatment. This finding stands in sharp contrast to the trajectory often seen after chemoradiotherapy for head and neck cancer, where studies have documented persistent declines in swallowing, dry mouth, and social functioning years after treatment completion. For a disease that disproportionately affects middle-aged adults, the ability to return to baseline function within a year represents a substantial practical benefit.

The biological rationale for the approach rests on the chemosensitivity of HPV-positive tumours. Viral oncogene-driven cancers undergo apoptosis more readily when exposed to DNA-damaging agents, and prior pathological studies of p16-positive oropharyngeal carcinoma have shown deep tumour regression after neoadjuvant chemotherapy. By administering chemotherapy before any local therapy, clinicians can also gauge response directly: the surgical specimen provides definitive pathological evidence of how completely the tumour was eradicated. Patients whose specimens show residual disease can still receive postoperative radiation or chemoradiotherapy as salvage, which is precisely why the trial design preserved standard adjuvant treatment for the minority who needed it.

The trial’s limitations are those inherent to a single-arm Phase II study of modest size. Without a randomised control group, the durability of disease control and survival cannot be established, and longer follow-up will be required to confirm that avoiding radiation does not compromise cure rates in the 91 percent of patients who skipped it. The primary endpoint threshold was not met, meaning the results cannot by themselves change practice guidelines. Nevertheless, the investigators argue that the combination of a 65.6 percent pathological complete response rate, near-universal R0 resection, molecular clearance of circulating tumour HPV DNA in most patients, and full quality-of-life recovery constitutes a compelling signal that deserves testing in larger, ideally randomised, Phase III studies.

The findings arrive amid a rapidly evolving landscape of de-escalation research. Recent trials have explored neoadjuvant immunotherapy combined with chemotherapy before transoral surgery, including studies of nivolumab and sintilimab, and long-term follow-up of E3311 has continued to support risk-based adjuvant treatment decisions after robotic surgery. The Japanese trial adds an important data point: chemotherapy-first sequencing can convert a substantial fraction of HPV-associated oropharyngeal cancers into surgically curable disease without any radiation exposure. If ongoing and future studies confirm these results, the standard of care for HPV-positive throat cancer could shift decisively away from radiotherapy-based regimens toward response-adapted strategies in which the intensity of treatment is tailored to how completely each patient’s tumour responds to initial systemic therapy.

Subject of Research: Neoadjuvant triplet chemotherapy as a radiotherapy-sparing strategy for HPV-associated oropharyngeal squamous cell carcinoma

Article Title: Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus–associated oropharyngeal cancer: a multicentre Phase II trial

Article References: Yokota, T., Tsuzuki, T., Onitsuka, T., Iizuka, A., Ouchi, Y., Mori, T., Tsukahara, K., Hanyu, K., Mukaigawa, T., Nakashima, T., Uryu, H., Omura, G., Nakamura, H., Uemura, H., Nishikawa, D., Kano, S., Akiyama, Y., Onoe, T., Oyamada, S., & Yamaguchi, T. (2026). Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus–associated oropharyngeal cancer: a multicentre Phase II trial. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03610-y

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03610-y

Keywords: HPV-associated oropharyngeal cancer, neoadjuvant chemotherapy, NAC-TPF, transoral surgery, radiotherapy de-escalation, pathological complete response, circulating tumor HPV DNA, Phase II trial, quality of life, head and neck cancer, British Journal of Cancer, treatment de-escalation